Telix Pharmaceuticals Ltd.

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Novo Nordisk is investing DKK 120 million ($16.5 million) into Denmark’s new manufacturing learning center called Campus Kalundborg, which is envisioned to grow the local student population to 1,500 by 2030. The Novo Nordisk Foundation is also investing DKK 202 million ($27.9 million) for teaching and training resources until 2031. In total, more than DKK 320 million ($44 million) is being invested. Telix Pharmaceuticals is acquiring a Californian research facility and its employees, a few early clinical-stage assets and biologics technology from antibody engineering company ImaginAb, according to a Monday release. No financial details were disclosed. Telix is also taking control of sales and marketing of its bone infection imaging asset, dubbed Scintimun, which it previously outlicensed to Curium Pharma, the company said Monday. Telix plans on researching Scintimun in combination with its Phase 2 bone marrow stem cell asset, called TLX66 (90Y-besilesomab). Curium will still manufacture Scintimun for Telix. Scintimun was EMA approved in January 2010. Charles River Laboratories is using Akron Bio’s line of liquid cytokines in its cell therapy manufacturing platform, the companies said Thursday. Cytiva and Cellular Origins are partnering to combine their cell therapy manufacturing platforms, according to a Thursday release. Isotope producer Nusano and Atley Solutions are partnering to establish a commercial supply chain for the radioisotope Astatine-211, the companies announced Thursday. ReciBioPharm, owned by CDMO Recipharm, has secured a three-year grant from the Bill & Melinda Gates Foundation to distribute its manufacturing tech to low and middle-income countries, the company said Monday. The technology is used to scale up manufacturing of RNA-based medicines. Emergent BioSolutions has received $16.7 million from the Center for the Biomedical Advanced Research and Development Authority (BARDA) to further develop and test its Zaire Ebola virus drug called Ebanga. This is its second contract option from BARDA; the original 10-year contract for Ebanga was signed in July 2023. Diagnostic solutions company Sysmex America is planning to build a new manufacturing and distribution facility in São José dos Pinhais, Brazil, the company said Wednesday. Construction is expected to start in the second quarter of 2025. Cell therapy CDMO BioCentriq is partnering with tech consultancy firm Orchestra Life Sciences, which will provide its manufacturing platform for BioCentriq’s new 60,000-square-foot Princeton, NJ facility. Orchestra will also help design the factory, according to a Tuesday release. CDMO Kindeva Drug Delivery and RNA vaccine tech company Emervax are collaborating to develop a new vaccine delivery method. Kindeva has given Emervax access to its microneedle vaccine patch, which Emervax will use with its RNA tech platform, according to a Jan. 9 press release. Alcami Corporation CEO Bill Humphries has stepped down and will be replaced by Patrick Walsh who will serve as interim CEO, the company said Monday. Walsh has previously acted as CEO of Alcami twice and has been chairman of the board for the past four years. International Isotopes is expanding its footprint by purchasing a 1.77-acre plot of land to build a 50,000-square-foot factory. Further, the company is leasing a new 8,600-square-foot building. ITM Isotope Technologies Munich is supplying the radioisotope Actinium-225 to Ariceum Therapeutics for its radiopharma pipeline, including its lead asset called satoreotide which is being investigated for certain cancers, according to the Monday release. Inhaler drugmaker Iconovo and Lonza are partnering to develop a spray-dried formula for Iconovo’s nasal device dubbed ICOone Nasal. Lonza will develop the formulation at its Bend, OR, factory, according to the Monday release.

With acquisitions across the supply chain and fresh approvals expected in 2025, Telix are entrenching their position in the radiopharmaceuticals market. Love Employee/ Getty Images Following a year thick with acquisitions across the radiopharmaceutical supply chain, Telix Pharmaceuticals has announced a 55% year-on-year revenue increase in 2024. CEO Christian Behrenbruch described the Australian company’s success in a presentation at the 2025 JP Morgan Healthcare Conference on 15 January in San Francisco. After a flurry of acquisitions, Behrenbruch announced Telix superseded its 2024 revenue guidance, generating $517m as its stock continues to rise. In 2025, Behrenbruch said Telix expects to launch three new products to the US market pending US Food and Drug Administration (FDA) approval. These include Gozellix (TLX007-CDx) for PSMA imaging of prostate cancer and Pixclara (TLX101-CDx) for glioblastoma imaging with Prescription Drug User Fee Act (PDUFA) dates set for 24 March and 26 April, respectively, as well as Zircaix (TLX250-CDx) for kidney cancer imaging for which a PDUFA date is expected around August to September. Nonetheless, the past year was not full of successes for Telix. In January, the company announced plans for a US initial public offering (IPO), but in June it withdrew its bid , with executives blaming market conditions at the time. Still, at the same time, the company went on an acquisition spree, starting with Canadian isotope producer ARTMS in March for $575m, IsoTherapeutics in April for $8.1m plus milestone payments, and QSAM Biosciences in May for 123.1m, and also purchased RLS Radiopharmacies in September for $230m. With these acquisitions, Telix has built a network of isotope production and distribution facilities across the US and R&D operations in US and Canada. Telix also plans to expand the approval of its lead product Illuccix (TLX591-CDx) for prostate cancer imaging into the EU, UK, and Brazil, with Phase III bridging studies completed in China and underway in Japan. Approved by the FDA in December 2021, Illuccix generated $357.9m in H1 2024 global sales as per a Telix report, accounting for the majority of the company’s revenue. Behrenbruch stated Telix will continue to maintain focus on beta-emitting assets like Illuccix in its pipeline, but that the company is also investing in several alpha-emitters as part of its next-generation isotope platform. Telix’s most advanced clinical asset is TLX591 (Lu-177 rosopatamab tetraxetan), a beta-emitting antibody conjugate being studied in the Phase III ProSTACT GLOBAL trial (NCT04876651) to treat castration-resistant prostate cancer. Interim data from part 1 of the trial is expected in late H1 2025, according to Behrenbruch. Alongside TLX591, Behrenbruch said Telix expects initiate pivotal trials for Zircaix in clear cell renal carcinoma and Pixclara in recurring glioblastoma in 2025.

Telix Pharmaceuticals said today’s acquisition was a good synergistic fit for its existing portfolio. \n Telix Pharmaceuticals’ expansion phase shows no sign of running out yet, with the Australian radiopharma company paying $45 million in upfront cash and equity for a pipeline of preclinical cancer antibodies and a Californian research facility.The therapies and facility belong to U.S.-based radiopharma ImaginAb, which, along with the $10 million cash payment and $35 million equity investment, could be in line for $185 million in potential milestone payments from Telix. At the center of the deal are various early-stage drugs aimed at “high-value targets” like delta-like protein 3 (DLL3) and integrin αvβ6 “as well as several other novel targets in discovery stage,” Telix explained in a Jan. 13 release.Telix had at one point last year been lining up a $200 million Nasdaq IPO but had second thoughts at the last minute. Instead, the company has channeled its energies into fleshing out its radiopharma capabilities, including the $13.6 million acquisition of Texas-based CDMO IsoTherapeutics, the $82 million purchase of ARTMS  and its cyclotron-based isotope production platform and the acquisition of RLS Radiopharmacies to secure access to RLS’ network of 31 radiopharmacies across the U.S. The Australian company said today’s acquisition was a good synergistic fit for its existing portfolio. ImaginAb’s use of “small engineered antibody formats that enable highly specific cancer targeting, combined with fast tumor uptake and blood clearance … has the potential to be highly effective for imaging and treating tumors with a broad range of radioisotopes, with alpha emitters of particular interest,” Telix explained in a release.Along with the drugs, Telix will also take over ImaginAb’s Californian research facility and its staff.“Together, these assets will provide Telix with further in-house capabilities in antibody engineering and preclinical development, as well as a novel biologics platform to create the next generation of Telix precision medicine and therapeutic products, beyond the current clinical-stage pipeline,” the company said.“The combination of a proprietary drug discovery platform, pipeline of promising theranostic assets and a talented team of subject matter experts will enhance Telix’s research and innovation capability now and into the future,” Telix CEO Richard Valeix said in the release. “This acquisition will enable Telix to explore new disease areas with state-of-the-art radiotherapeutic technology.”